{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:18:19Z","timestamp":1775312299503,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Danish Froehlich Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.rmed.2020.106260","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T20:57:18Z","timestamp":1606424238000},"page":"106260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Oral corticosteroid sparing effects of anti-IL5\/ anti-IL5 receptor treatment after 2 years of treatment"],"prefix":"10.1016","volume":"176","author":[{"given":"Anne Sofie","family":"Bjerrum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Skjold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes Martin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2020.106260_bib1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2020.106260_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"13","key":"10.1016\/j.rmed.2020.106260_bib3","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma [published correction appears in N Engl J Med. 2015 Apr 30;372(18):1777]","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9842","key":"10.1016\/j.rmed.2020.106260_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.rmed.2020.106260_bib5","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.rmed.2020.106260_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rmed.2020.106260_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"13","key":"10.1016\/j.rmed.2020.106260_bib8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.rmed.2020.106260_bib9","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2020.106260_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.rmed.2020.106260_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.rmed.2020.106260_bib12","first-page":"1","article-title":"Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma [published online ahead of print, 2019 Sep 3]","author":"Pertzov","year":"2019","journal-title":"J. Asthma"},{"key":"10.1016\/j.rmed.2020.106260_bib13","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212584","article-title":"Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice","volume":"8","author":"Montero-P\u00e9rez","year":"2019","journal-title":"Drugs Context"},{"issue":"12","key":"10.1016\/j.rmed.2020.106260_bib14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17476348.2019.1676734","article-title":"Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response","volume":"13","author":"Caminati","year":"2019","journal-title":"Expet Rev. Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2020.106260_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European respiratory society\/American thoracic society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2020.106260_bib17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/1744666X.2019.1653758","article-title":"Real-life studies of biologics used in asthma patients: key differences and similarities to trials","volume":"15","author":"Heffler","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.rmed.2020.106260_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.rmed.2020.106260_bib19","article-title":"Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma","volume":"8","author":"Pelaia","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"10.1016\/j.rmed.2020.106260_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6 months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2020.106260_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real world effectiveness of benralizumab in severe eosinophilic asthma","author":"Kavanagh","year":"2020","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611120304005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611120304005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:16:12Z","timestamp":1760616972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611120304005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"alternative-id":["S0954611120304005"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2020.106260","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral corticosteroid sparing effects of anti-IL5\/ anti-IL5 receptor treatment after 2 years of treatment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2020.106260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106260"}}